Fresenius moves forward with two U.S. expansions after killing Akorn deal

Fresenius Kabi missed an opportunity to quickly bulk up in sterile manufacturing when its $5 billion deal to buy Akorn imploded last year but its organic expansion efforts in the U.S. are moving forward.